Other Programs
In addition to our three clinical-stage product candidates, we have one product candidate in IND-track development:
AM-831
We have discovered and, in collaboration with Meiji Seika Kaisha, are developing AM-831, a small molecule product candidate for the treatment of schizophrenia and related disorders. AM-831 was selected from a series of compounds that provide the potential for a new class of pro-cognitive antipsychotic drugs. These compounds combine muscarinic m1 agonism with actions on both dopamine and serotonin receptors. AM-831 has demonstrated effects in animal models of psychosis and pro-cognitive effects in animal models of cognition.
We are in IND-track development with AM-831. We intend to co-develop this compound in collaboration with Meiji Seika Kaisha through completion of proof-of-concept clinical studies. Meiji Seika Kaisha has exclusive rights to develop and commercialize the product in Japan and several other Asian countries. ACADIA retains the right to develop and commercialize the product in the rest of the world, including the United States and Europe.
Other Programs
In addition to our four most advanced product candidates currently in development, we have used our proprietary drug discovery platform to discover additional product candidates. These include our ER-beta program where we have discovered compounds that may possess anti-inflammatory and neuroprotective properties and may have the ability to slow down the progression of Parkinson's disease. Our current research studies of these ER-beta compounds are supported by a grant from the Michael J. Fox Foundation.
Currently, our resources are focused on our most advanced product candidates, including pimavanserin, and we are not devoting significant resources to earlier-stage programs that are not directly funded. However, we may elect to pursue the development of additional product candidates in the future either independently or in partnerships.
back to top